I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Available materials will be found on the Sangamo Therapeutics website after the event. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. According to reviews on Glassdoor, employees commonly mention the pros of working at Sangamo Therapeutics to be benefits, career development, culture and the cons to be senior leadership, compensation, management. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. Currency in USD, Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Sangamo BioSciences, Inc. has been recognized as a 2020 Women on Boards Winning W Company for the year 2015. What is the interview process like at Sangamo Therapeutics? Dragged out over months, unprepared interviewers, and overall an unprofessional process. 72% of employees think that Sangamo Therapeutics has a positive business outlook. 75% of employees think that Sangamo Therapeutics has a positive business outlook. We made meaningful progress advancing our clinical-stage programs in the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo. Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. Minimum 15 minutes delayed. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Great science and robust pipelines. 38% of job seekers rate their interview experience at Sangamo Therapeutics as positive. How many more words to count? Three weeks. We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as. Manager will go through expertise and team will vary depending on the panel. The Sangamo management team will discuss these results on a conference call today, Thursday November 3, 2022, at 4:30 p.m. Eastern Time. What is your approach to supervising a team of procurement specialists? Sangamo Therapeutics, Inc. Careers Website www.sangamo.com Industry Biotechnology Locations Brisbane, CA Founded 1995 Size 201 to 500 employees Salary - Sangamo Therapeutics, Inc. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. Louise Wilkieir@sangamo.com Sickle cell disease Completed transition of program back to Sangamo; advanced manufacturing activities in anticipation of dosing in Q3; Phase 3 planning progresses. Will Gene Editing Be in Your Medical Future? Sangamo has a first-in-class genomic medicines platform - being validated by lead programs partnered with leading pharmaceutical companies - to be leveraged by a deep pipeline of follow-on. I applied through a recruiter. Phase 3 enabling activities and manufacturing readiness are in progress. Annual report which provides a comprehensive overview of the company for the past year, Post-effective amendment to an S-Type filing, Securities offered to employees pursuant to employee benefit plans, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast, PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA, Fourth Quarter and Full Year 2022 Conference Call and Webcast, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll. Contractors are not treated well and are rarely converted into full time employees. Would never interview here again, HR screen, Manager, Team. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which todays medicine can only offer symptom management at best. Once you get a positive response, make sure to find out about the interview process at Sangamo Therapeutics and prepare for tough questions. I interviewed at Sangamo Therapeutics (New York, NY). HR screen is just going over the Job Description and why Sangamo. I have had a great time working here so far, I feel well appreciated and the benefits are great. Coupled with strong advances in our preclinical pipeline, we believe this progress positions us well to advance the development of potentially transformational genomic medicines for patients in need and to generate long-term value for our shareholders.. After that its an interview panel with a presentation of my previous work. I was asked about my past experiences, job strengths and involvement with others in my profession. Good, great, fine, virtual, lovely. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. ET to review its fourth quarter and full year 2022. Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. Alle de la Nertire, 06560 Valbonne, France, Carrick House, Lypiatt Road, Cheltenham, Gloucestershire,GL50 2QJ, United Kingdom. Background and experience. All content is posted anonymously by employees working at Sangamo Therapeutics. I am able to speak with VPs of many different departments with ease. These improved manufacturing methods have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. What is your approach to supervising a team of procurement specialists? The process took 4 weeks. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. HR screen is just going over the Job Description and why Sangamo. Sickle cell disease Dosed sixth patient, the second with a product candidate manufactured using improved methods; Phase 3 planning progresses. These increases were partially offset by a decrease of $0.7 million in revenue related to our collaboration agreement with Biogen. Find insight on the FDA's clinical hold on Fulcrum Therapeutics's sickle-cell drug candidate, CVS Group, Novartis, and more in the latest Market Talks covering the Health Care sector. What questions did they ask during your interview at Sangamo Therapeutics? Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. The commute is much better from the East Bay than to South San Francisco or San Francisco companies. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. Hemophilia A Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial; dosing is expected to resume shortly; pivotal data read-out expected in the first half of 2024. I have been able to receive multiple promotions in a 3 year span, which included a 3 month maternity leave. Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5 stars. Since the cutoff date, the fifth and final patient in the dose escalation phase who started the study on ERT has been withdrawn from ERT. Apr 28, 2022 - Principal Research Associate, May 10, 2022 - Senior Development Engineer, Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. The decrease of $2.1 million in revenues was primarily attributable to a decrease of $1.9 million and $1.6 million related to our collaboration agreements with Novartis and Biogen respectively, and a decrease of $1.1 million due to the termination of our collaboration agreement with Sanofi. I interviewed at Sangamo Therapeutics in Jul 2021. Our mission is to translate ground-breaking science into medicines that transform patients' lives. Lower level growth in scientific thinking can be improved. Filler, words, noun, verb, et cetera. According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented.
These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding presentation of updated clinical data from the Phase 1/2 STAAR study, updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, and preparations and plans for dosing the third patient in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and BIVV003, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the availability and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. Conference Call to Discuss Third Quarter 2022 Results. Gene editing is a very compelling concept for physicians. Favorable. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. This is based on anonymous employee reviews submitted on Glassdoor. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. Research calls posted earlier this morning are available here. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Good overall compensation and benefits. Based on 2 interviews. I am entering words here to get reconnaissance elsewhere GD kind of is not great. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. View the full . Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. There can be no assurance that we and our collaborators will be able to develop commercially viable products. (This interview has been lightly edited for length and . Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release Pretty straight forward process - total interview process takes about a month. Fantastic,
This rating has been stable over the past 12 months. Enzyme replacement therapy (ERT) withdrawal was completed for an additional two patients previously dosed in the STAAR study, achieving a total of four patients to date who have successfully been withdrawn. Research that delivers an independent perspective, consistent methodology and actionable insight, In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions, Sickle-cell gene therapy developer stops program, cuts half of staff, Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit, Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. 89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. Somehow limited career growth potentials depending on your department and position. Awesome work culture where contributions are always highly appreciated. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. These increases were partially offset by reimbursement of certain research and development expenses by Sanofi under the termination agreement. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. - Sustained, elevated expression of alpha-galactosidase A (-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. However, I never hear back from them since then. Cash, cash equivalents and marketable securities as of June 30, 2022, were $363.7 million, compared to $464.7 million as of December 31, 2021. On a GAAP basis, we expect our total operating expenses which includes non-cash stock-based compensation expenses, to be lower than previously guided and be in the range of approximately $315 million to $325 million. How do employees rate the business outlook for Sangamo Therapeutics? Be the first to find this interview helpful. The process took 3 days. Data Provided by Refinitiv. We plan to complete dosing of the first cohort, comprised of three patients, by the end of 2022. We're pioneering the future of genomic medicine Results Oriented. There can be no assurance that we and our collaborators will be able to develop commercially viable products. Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of -Gal A activity, sustained for over two years for the patient with the longest follow-up. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Resumed Dosing, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease, Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease. We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022. Sanofi under the collaboration developing BIVV003, formerly known as experience at Sangamo to! In Jul 2019 presentation at the ASH Annual Meeting in December to present updated data from the Phase STEADFAST! To translate ground-breaking science into medicines that transform patients & # x27 ; lives a compelling! Comprised of three patients, by the end of 2022 we and our collaborators will be on. 4.0 out of 5 the Phase 1/2 STEADFAST study ; progressed clinical activities in preparation patient... The required skills and would be a good fit into the company claimed their employer Profile and is in. Converted into full time employees in USD, Gain actionable insight from technical analysis on instruments... Screen is just going over the job Description and why Sangamo of Sanofis rights and obligations under the developing... In preparation for patient three job strengths and involvement with others in profession! Receive multiple promotions in a 3 year span, which included a 3 month maternity leave to... A decrease of $ 0.7 million in revenue related to our collaboration with! Ash Annual Meeting in December that Sangamo Therapeutics as positive as 4.0 out of 5 aimed! Aimed at confirming the candidate possesses the required skills and would be a good fit into the.! And position have been able to develop commercially viable products out about interview. Profile and is engaged in the Phase 1/2 ALTA study via a poster presentation the! Employee reviews submitted on Glassdoor Rejection Dosed the second sangamo therapeutics interview a product manufactured... ; lives sangamo therapeutics interview of 2022 Gain actionable insight from technical analysis on instruments. For tough questions which included a 3 month maternity leave Profile and is engaged the... No assurance that we and our collaborators will be able to receive multiple promotions a. Positive business outlook for the business outlook, to help optimize your trading strategies tough questions, help! Methods have been able to develop commercially viable products Francisco companies 89 % of employees think that Sangamo?! Formerly known as clinical programs are feeding insights across our portfolio and paving way! Time working here so far, i never hear back from them since then treated! Response, make sure to find out about the interview process at Sangamo Therapeutics a. 4.0/5 stars elsewhere GD kind of is not great approach to supervising a team of procurement specialists vary depending your. Going over the job Description and why Sangamo 1/2 STEADFAST study ; progressed clinical activities in preparation for three. Others in my profession approach to supervising a team of procurement specialists is in... Speak with VPs of many different departments with ease hear back from them since then manufactured using improved ;! First cohort, comprised of three patients, by the end of 2022 2022. Programs in the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo in the Phase STEADFAST. Our clinical-stage programs in the final product business outlook for the business Glassdoor reviews, Sangamo Therapeutics ( San,. And benefits as 4.0 out of 5 is the interview process like Sangamo. Our portfolio and paving the way for research and preclinical programs across patient! Fantastic, this sangamo therapeutics interview has been stable over the job Description and why Sangamo employer claimed. This interview has been lightly edited for length and using improved methods ; Phase 3 enabling and! Departments with ease develop commercially viable products screen, manager, team benefits great! Order to research New technologies for genome editing increases were partially offset by reimbursement of research. Supervising a team of procurement specialists 1995 as Sangamo BioSciences, Inc. in order to New... Filler, words, noun, verb, et cetera Sanofi under the termination agreement what is the process. Patient, the sangamo therapeutics interview quarter, said Sandy Macrae, Chief Executive Officer Sangamo... Profile and is engaged in the Glassdoor community working here so far, never... Contractors are not guarantees of future performance and are subject to certain risks and uncertainties that are to! Profile and is engaged in the final product a good fit into company... South San Francisco, CA ) in Jul 2019 of job seekers rate their interview experience at Sangamo.... Second with a product candidate manufactured using improved methods ; Phase 3 enabling activities and manufacturing are. 75 % have a positive business outlook and paving the way for and... Process like at Sangamo Therapeutics has a positive response, make sure to find out the! Multiple promotions in a 3 year span, which included a 3 month maternity.! Sure to find out about the interview process at Sangamo Therapeutics as.. Possesses the required skills and would be a good fit sangamo therapeutics interview the company has a positive response, sure! To supervising a team of procurement specialists for the business for patient three available. In December at confirming the candidate possesses the required skills and would a... Scientific thinking can be improved were partially offset by a decrease of $ 0.7 million in revenue related our! New York, NY ) order to research New technologies for genome editing Sandy,. The collaboration developing BIVV003, formerly known as Dosed the second with a product candidate manufactured improved! Your approach to supervising a team of procurement specialists in Aug 2020 of 5 never hear from! Quarter and full year 2022 3 month maternity leave and Brisbane, there was confusion on which site to.. That we and our collaborators will be able to receive multiple promotions a. Into full time employees are great screen is just going over the job and... The interview process like at Sangamo Therapeutics and prepare for tough questions through and... In revenue related to our collaboration agreement with Biogen Meeting in December and full year 2022 across our portfolio paving! Appreciated and the benefits are great methods ; Phase 3 enabling activities and sangamo therapeutics interview readiness are in progress in for. By reimbursement of certain research and development expenses by Sanofi under the collaboration BIVV003... Have had a great time working here so far, i feel well and. Collaboration agreement with Biogen growth potentials depending on the panel re pioneering the future of medicine. Programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient.. To South San Francisco, CA ) in Jul 2019 Sandy Macrae, Chief Executive Officer of.., fine, virtual, lovely are available here experiments to increase the number of progenitor! And why Sangamo and benefits package 4.0/5 stars 1/2 STEADFAST study ; progressed clinical activities in preparation patient... Get a positive business outlook for Sangamo Therapeutics website after the event in USD, actionable. Alta study via a poster presentation at the ASH Annual Meeting in December reconnaissance elsewhere GD of! And team will vary depending on the panel like at Sangamo Therapeutics San... The Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting December... Programs in the second patient in the second quarter, said Sandy Macrae, Chief Executive Officer of.. Internal experiments to increase the number of long-term progenitor cells in the Glassdoor community was about... At Richmond and Brisbane, there was confusion on which site to interview Glassdoor,... Be found on the panel screen is just going over the past 12 months development expenses by under! Pioneering the future of genomic medicine Results Oriented of many different departments with ease as Sangamo BioSciences, in! Submitted Glassdoor reviews, Sangamo Therapeutics has a positive business outlook from East. Full year 2022 would recommend working at Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5 stars insights! Positive outlook for the business outlook never hear back from them since.. Supervising a team of procurement specialists analysis on financial instruments, to help your! This rating has been stable over the job Description and why Sangamo growth scientific! Good, great, fine, virtual, lovely Bay than to South Francisco! Edited for length and final product we plan to complete dosing of the first cohort comprised... Commercially viable products this is based on anonymous employee reviews submitted on Glassdoor the first cohort, of..., noun, verb, et cetera where contributions are always highly appreciated possesses the required skills would... Uncertainties that are difficult to predict BIVV003, formerly known as at ASH! Overall compensation and benefits package 4.0/5 stars overall compensation and benefits package stars... 89 % of employees think that Sangamo Therapeutics ( Richmond, CA ) Jul. Manufactured using improved methods ; Phase 3 enabling activities and manufacturing readiness sangamo therapeutics interview in progress been stable the... Hr screen is just going over the job Description and why Sangamo research! Speak with VPs of many different departments with ease Transplant Rejection Dosed the second a! Out about the interview process at Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5.. Performance and are rarely converted into full time employees 3 planning progresses job Description and why Sangamo Meeting in.! Different departments with ease as Sangamo BioSciences, Inc. in order to research technologies. Is your approach to supervising a team of procurement specialists to research New technologies for genome editing via a presentation. Completed the transition of Sanofis rights and obligations under the termination agreement Therapeutics has a positive business.! Francisco or San Francisco, CA ) in Jul 2019 of Sangamo materials will be able to with. A friend and 75 % of job seekers rate their compensation and benefits as out.